Literature DB >> 1320796

Immediate early and functional AP-1 cis-response elements are involved in the transcriptional regulation of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10).

J P Wymer1, C M Aprhys, T D Chung, C P Feng, M Kulka, L Aurelian.   

Abstract

Expression from the promoter of the herpes simplex virus type 2 (HSV-2) large subunit of ribonucleotide reductase (ICP10) is stimulated by co-transfection with DNA that encodes the virion protein Vmw65 previously shown to activate in trans the transcription of all IE genes (Wymer et al., 1989). Specific cis response elements involved in ICP10 transcriptional regulation were studied by chloramphenicol acetyltransferase analysis with hybrid ICP10 promoter/CAT structural gene constructions containing wild type or site-directed mutations of the promoter sequences. The data indicate that Vmw65 activation requires an intact TAAT-GARAT motif while complex formation requires an intact Oct-1 element, and the AP-1 consensus elements in the ICP10 promoter are functional in vitro. Thus, expression from the wild type and GA-rich mutant constructions was enhanced 10-20-fold by co-transfection with DNA encoding Vmw65. The GARAT and POU homeobox (PHB) binding motifs were required for Vmw65 mediated activation but the mutant in the POU specific box (PSB) binding motif was activated at higher concentrations of Vmw65 DNA (1.0-3.0 micrograms). The PHB and PSB binding motifs were necessary for complex formation as determined by gel retardation analysis with in vitro synthesized OTF-1 and Vmw65 proteins. The GARAT and GA-rich elements were not required. CAT expression from pICP10-cat was enhanced by co-transfection with jun and fos encoding DNA, and the ICP10 promoter complexed with in vitro synthesized jun protein.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320796     DOI: 10.1016/0168-1702(92)90112-m

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  8 in total

1.  The growth compromised HSV-2 mutant DeltaRR prevents kainic acid-induced apoptosis and loss of function in organotypic hippocampal cultures.

Authors:  Michael D Gober; Jennifer M Laing; Scott M Thompson; Laure Aurelian
Journal:  Brain Res       Date:  2006-10-03       Impact factor: 3.252

2.  Ras-GAP binding and phosphorylation by herpes simplex virus type 2 RR1 PK (ICP10) and activation of the Ras/MEK/MAPK mitogenic pathway are required for timely onset of virus growth.

Authors:  C C Smith; J Nelson; L Aurelian; M Gober; B B Goswami
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) blocks apoptosis in hippocampal neurons, involving activation of the MEK/MAPK survival pathway.

Authors:  D Perkins; E F R Pereira; M Gober; P J Yarowsky; L Aurelian
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

4.  Analysis of bovine herpesvirus 1 transcripts during a primary infection of trigeminal ganglia of cattle.

Authors:  L M Schang; C Jones
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

Review 5.  Cervical cancer: is herpes simplex virus type II a cofactor?

Authors:  C Jones
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

6.  Induction of herpes simplex virus type 1 immediate-early gene expression by a cellular activity expressed in Vero and NB41A3 cells after growth arrest-release.

Authors:  W M Ralph; M S Cabatingan; P A Schaffer
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

7.  The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for immediate-early gene expression and virus growth.

Authors:  C C Smith; T Peng; M Kulka; L Aurelian
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

8.  Characterization of the novel protein kinase activity present in the R1 subunit of herpes simplex virus ribonucleotide reductase.

Authors:  J Cooper; J Conner; J B Clements
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.